|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marin JJ, Al-Abdulla R, Lozano E, Briz O,
Bujanda L, Banales JM and Macias RI: Mechanisms of resistance to
chemotherapy in gastric cancer. Anticancer Agents Med Chem.
16:318–334. 2016. View Article : Google Scholar
|
|
5
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garrido M, Fonseca PJ, Vieitez JM, Frunza
M and Lacave AJ: Challenges in first line chemotherapy and targeted
therapy in advanced gastric cancer. Expert Rev Anticancer Ther.
14:887–900. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng T, Wang J, Chen X and Liu L: Role of
microRNA in anticancer drug resistance. Int J Cancer. 126:2–10.
2010. View Article : Google Scholar
|
|
8
|
Dembinski JL and Krauss S:
Characterization and functional analysis of a slow cycling stem
cell-like subpopulation in pancreas adenocarcinoma. Clin Exp
Metastasis. 26:611–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Terry S, Savagner P, Ortiz-Cuaran S,
Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into
the role of EMT in tumor immune escape. Mol Oncol. 11:824–846.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toledo-Guzmán ME, Bigoni-Ordóñez GD,
Ibáñez Hernández M and Ortiz-Sánchez E: Cancer stem cell impact on
clinical oncology. World J Stem Cells. 10:183–195. 2018. View Article : Google Scholar
|
|
13
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Catalano V, Di Franco S, Iovino F, Dieli
F, Stassi G and Todaro M: CD133 as a target for colon cancer.
Expert Opin Ther Targets. 16:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eyre R, Harvey I, Stemke-Hale K, Lennard
TW, Tyson-Capper A and Meeson AP: Reversing paclitaxel resistance
in ovarian cancer cells via inhibition of the ABCB1 expressing side
population. Tumour Biol. 35:9879–9892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential Paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao J: Cancer stem cells and
chemoresistance: The smartest survives the raid. Pharmacol Ther.
160:145–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sahu A, Singhal U and Chinnaiyan AM: Long
noncoding RNAs in cancer: From function to translation. Trends
Cancer. 1:93–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Q, Zhang RW, Sui PC, He HT and Ding
L: Dysregulation of non-coding RNAs in gastric cancer. World J
Gastroenterol. 21:10956–10981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ayers D and Vandesompele J: Influence of
microRNAs and long non-coding RNAs in cancer chemoresistance. Genes
(Basel). 8:82017. View Article : Google Scholar
|
|
23
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riquelme I, Letelier P, Riffo-Campos AL,
Brebi P and Roa JC: Emerging role of miRNAs in the drug resistance
of gastric cancer. Int J Mol Sci. 17:4242016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matuszcak C, Haier J, Hummel R and Lindner
K: MicroRNAs: Promising chemoresistance biomarkers in gastric
cancer with diagnostic and therapeutic potential. World J
Gastroenterol. 20:13658–13666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Delás MJ and Hannon GJ: lncRNAs in
development and disease: From functions to mechanisms. Open Biol.
7:72017. View Article : Google Scholar
|
|
28
|
Heery R, Finn SP, Cuffe S and Gray SG:
Long non-coding RNAs: Key regulators of epithelial-mesenchymal
transition, tumour drug resistance and cancer stem cells. Cancers
(Basel). 9. pp. 92017, View Article : Google Scholar
|
|
29
|
Yuan L, Xu B, Yuan P, Zhou J, Qin P, Han
L, Chen G, Wang Z, Run Z, Zhao P, et al: Tumor-infiltrating
CD4+ T cells in patients with gastric cancer. Cancer
Cell Int. 17:1142017. View Article : Google Scholar
|
|
30
|
Wang LL, Zhang XH, Zhang X and Chu JK:
MiR-30a increases cisplatin sensitivity of gastric cancer cells
through suppressing epithelial-to-mesenchymal transition (EMT). Eur
Rev Med Pharmacol Sci. 20:1733–1739. 2016.PubMed/NCBI
|
|
31
|
Archie V, Kauh J, Jones DV Jr, Cruz V,
Karpeh MS Jr and Thomas CR Jr: Gastric cancer: Standards for the
21st century. Crit Rev Oncol Hematol. 57:123–131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang XL, Shi HJ, Wang JP, Tang HS and Cui
SZ: MiR-218 inhibits multidrug resistance (MDR) of gastric cancer
cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol.
8:6397–6406. 2015.PubMed/NCBI
|
|
34
|
An Y, Zhang Z, Shang Y, Jiang X, Dong J,
Yu P, Nie Y and Zhao Q: miR-23b-3p regulates the chemoresistance of
gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis.
6:e17662015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Lu Q and Cai X: MicroRNA-106a
induces multidrug resistance in gastric cancer by targeting RUNX3.
FEBS Lett. 587:3069–3075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kondo T, Wakayama T, Naiki T, Matsumoto K
and Sugimoto K: Recruitment of Mec1 and Ddc1 checkpoint proteins to
double-strand breaks through distinct mechanisms. Science.
294:867–870. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Özeş AR, Miller DF, Özeş ON, Fang F, Liu
Y, Matei D, Huang T and Nephew KP: NF-κB-HOTAIR axis links DNA
damage response, chemoresistance and cellular senescence in ovarian
cancer. Oncogene. 35:5350–5361. 2016. View Article : Google Scholar
|
|
38
|
Lin CT, Lyu YL, Xiao H, Lin WH and
Whang-Peng J: Suppression of gene amplification and chromosomal DNA
integration by the DNA mismatch repair system. Nucleic Acids Res.
29:3304–3310. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferguson DO and Alt FW: DNA double strand
break repair and chromosomal translocation: Lessons from animal
models. Oncogene. 20:5572–5579. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zugazagoitia J, Guedes C, Ponce S, Ferrer
I, Molina-Pinelo S and Paz-Ares L: Current challenges in cancer
treatment. Clin Ther. 38:1551–1566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schlösser HA, Drebber U, Kloth M, Thelen
M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F,
Urbanski A, et al: Immune checkpoints programmed death 1 ligand 1
and cytotoxic T lymphocyte associated molecule 4 in gastric
adenocarcinoma. OncoImmunology. 5:e11007892015. View Article : Google Scholar
|
|
42
|
Jabbour E, Kantarjian H and Cortes J: Use
of second- and third-generation tyrosine kinase inhibitors in the
treatment of chronic myeloid leukemia: An evolving treatment
paradigm. Clin Lymphoma Myeloma Leuk. 15:323–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Szakács G, Jakab K, Antal F and Sarkadi B:
Diagnostics of multidrug resistance in cancer. Pathol Oncol Res.
4:251–257. 1998. View Article : Google Scholar
|
|
44
|
Tan B, Li Y, Zhao Q, Fan L and Wang D:
ZNF139 increases multidrug resistance in gastric cancer cells by
inhibiting miR-185. Biosci Rep. 38:382018. View Article : Google Scholar
|
|
45
|
Li Q, Wang JX, He YQ, Feng C, Zhang XJ,
Sheng JQ and Li PF: MicroRNA-185 regulates chemotherapeutic
sensitivity in gastric cancer by targeting apoptosis repressor with
caspase recruitment domain. Cell Death Dis. 5:e11972014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB,
Fang ZY, Cui SZ and Wang LT: MicroRNA-218 is upregulated in gastric
cancer after cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy and increases chemosensitivity to cisplatin. World J
Gastroenterol. 20:11347–11355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zeng JF, Ma XQ, Wang LP and Wang W:
MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering
effects by targeting CD44 in gastric cancer. World J Gastroenterol.
23:2337–2345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li G, Yang F, Gu S, Li Z and Xue M:
MicroRNA-101 induces apoptosis in cisplatin-resistant gastric
cancer cells by targeting VEGF-C. Mol Med Rep. 13:572–578. 2016.
View Article : Google Scholar
|
|
49
|
Bao J, Xu Y, Wang Q, Zhang J, Li Z, Li D
and Li J: miR-101 alleviates chemoresistance of gastric cancer
cells by targeting ANXA2. Biomed Pharmacother. 92:1030–1037. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang
J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR
cancer cells to the combination of doxorubicin and taxol by
inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang P, Li Z, Liu H, Zhou D, Fu A and
Zhang E: MicroRNA-126 increases chemosensitivity in drug-resistant
gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun.
479:91–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li
K, Zhou L, Sun Y, Li M, Zhou J, et al: miR-508-5p regulates
multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene. 33:3267–3276. 2014. View Article : Google Scholar
|
|
53
|
Shang Y, Feng B, Zhou L, Ren G, Zhang Z,
Fan X, Sun Y, Luo G, Liang J, Wu K, et al: The
miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of
gastric cancer. Oncotarget. 7:538–549. 2016. View Article : Google Scholar :
|
|
54
|
Du X, Liu B, Luan X, Cui Q and Li L:
miR-30 decreases multidrug resistance in human gastric cancer cells
by modulating cell autophagy. Exp Ther Med. 15:599–605.
2018.PubMed/NCBI
|
|
55
|
Li C, Zou J, Zheng G and Chu J: miR-30a
decreases multidrug resistance (MDR) of gastric cancer cells. Med
Sci Monit. 22:4509–4515. 2016. View Article : Google Scholar :
|
|
56
|
Teng R, Hu Y, Zhou J, Seifer B, Chen Y,
Shen J and Wang L: Overexpression of Lin28 decreases the
chemosensitivity of gastric cancer cells to oxaliplatin,
paclitaxel, doxorubicin, and fluorouracil in part vi a
microRNA-107. PLoS One. 10:e01437162015. View Article : Google Scholar
|
|
57
|
Kim H, Choi H and Lee SK: Epstein-Barr
virus miR-BART20-5p regulates cell proliferation and apoptosis by
targeting BAD. Cancer Lett. 356:733–742. 2015. View Article : Google Scholar
|
|
58
|
Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y
and Fan D: Methylation of miR-129-5p-CpG island modulates
multi-drug resistance in gastric cancer by targeting ABC
transporters. Oncotarget. 5:11552–11563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou L, Li X, Zhou F, Jin Z, Chen D, Wang
P, Zhang S, Zhuge Y, Shang Y and Zou X: Downregulation of
leucine-rich repeats and immunoglobulin-like domains 1 by
microRNA-20a modulates gastric cancer multidrug resistance. Cancer
Sci. 109:1044–1054. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a enhances cisplatin
resistance of human gastric cancer cell line by targeting NFKBIB.
Tumour Biol. 37:1261–1269. 2016. View Article : Google Scholar
|
|
61
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li X, Zhang Z, Yu M, Li L, Du G, Xiao W
and Yang H: Involvement of miR-20a in promoting gastric cancer
progression by targeting early growth response 2 (EGR2). Int J Mol
Sci. 14:16226–16239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang PF, Sheng LL, Wang G, Tian M, Zhu
LY, Zhang R, Zhang J and Zhu JS: miR-363 promotes proliferation and
chemo-resistance of human gastric cancer via targeting of FBW7
ubiquitin ligase expression. Oncotarget. 7:35284–35292.
2016.PubMed/NCBI
|
|
64
|
Fang Y, Shen H, Li H, Cao Y, Qin R, Long
L, Zhu X, Xie C and Xu W: miR-106a confers cisplatin resistance by
regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim
Biophys Sin (Shanghai). 45:963–972. 2013. View Article : Google Scholar
|
|
65
|
Danza K, Silvestris N, Simone G, Signorile
M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia
A, et al: Role of miR-27a, miR-181a and miR-20b in gastric cancer
hypoxia-induced chemoresistance. Cancer Biol Ther. 17:400–406.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhao Q, Li Y, Tan BB, Fan LQ, Yang PG and
Tian Y: HIF-1α induces multidrug resistance in gastric cancer cells
by inducing miR-27a. PLoS One. 10:e01327462015. View Article : Google Scholar
|
|
67
|
Zhao X, Yang L and Hu J: Down-regulation
of miR-27a might inhibit proliferation and drug resistance of
gastric cancer cells. J Exp Clin Cancer Res. 30:552011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Huang D, Wang H, Liu R, Li H, Ge S, Bai M,
Deng T, Yao G and Ba Y: miRNA27a is a biomarker for predicting
chemosensitivity and prognosis in metastatic or recurrent gastric
cancer. J Cell Biochem. 115:549–556. 2014. View Article : Google Scholar
|
|
69
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T,
Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al:
The sensitivity of gastric cancer to trastuzumab is regulated by
the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015.
View Article : Google Scholar
|
|
71
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jin B, Liu Y and Wang H: Antagonism of
miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell
Biochem Biophys. 72:275–282. 2015. View Article : Google Scholar
|
|
73
|
Eto K, Iwatsuki M, Watanabe M, Ida S,
Ishimoto T, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N,
et al: The microRNA-21/PTEN pathway regulates the sensitivity of
HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol.
21:343–350. 2014. View Article : Google Scholar
|
|
74
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017.
|
|
75
|
Shang C, Sun L, Zhang J, Zhao B, Chen X,
Xu H and Huang B: Silence of cancer susceptibility candidate 9
inhibits gastric cancer and reverses chemoresistance. Oncotarget.
8:15393–15398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y and
Fan D: Long noncoding RNA MRUL promotes ABCB1 expression in
multidrug-resistant gastric cancer cell sublines. Mol Cell Biol.
34:3182–3193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xu W, He L, Li Y, Tan Y, Zhang F and Xu H:
Silencing of lncRNA ZFAS1 inhibits malignancies by blocking
Wnt/β-catenin signaling in gastric cancer cells. Biosci Biotechnol
Biochem. 82:456–465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
YiRen H, YingCong Y, Sunwu Y, Keqin L,
Xiaochun T, Senrui C, Ende C, XiZhou L and Yanfan C: Long noncoding
RNA MALAT1 regulates autophagy associated chemoresistance via
miR-23b-3p sequestration in gastric cancer. Mol Cancer. 16:1742017.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Fang Q, Chen X and Zhi X: Long Non-Coding
RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases
Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
Med Sci Monit. 22:3506–3513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shang C, Guo Y, Zhang J and Huang B:
Silence of long noncoding RNA UCA1 inhibits malignant proliferation
and chemotherapy resistance to adriamycin in gastric cancer. Cancer
Chemother Pharmacol. 77:1061–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lan WG, Xu DH, Xu C, Ding CL, Ning FL,
Zhou YL, Ma LB, Liu CM and Han X: Silencing of long non-coding RNA
ANRIL inhibits the development of multidrug resistance in gastric
cancer cells. Oncol Rep. 36:263–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3. pp.
1351–1371. 2011, View Article : Google Scholar
|
|
83
|
Zhang Y, Xu W, Ni P, Li A, Zhou J and Xu
S: MiR-99a and MiR-491 regulate cisplatin resistance in human
gastric cancer cells by targeting CAPNS1. Int J Biol Sci.
12:1437–1447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang X, Yao J, Guo K, Huang H, Huai S, Ye
R, Niu B, Ji T, Han W and Li J: The functional mechanism of
miR-125b in gastric cancer and its effect on the chemosensitivity
of cisplatin. Oncotarget. 9:2105–2119. 2017.
|
|
85
|
Wang Z and Ji F: Downregulation of
microRNA-17-5p inhibits drug resistance of gastric cancer cells
partially through targeting p21. Oncol Lett. 15:4585–4591.
2018.PubMed/NCBI
|
|
86
|
Qian X, Xu W, Xu J, Shi Q, Li J, Weng Y,
Jiang Z, Feng L, Wang X, Zhou J, et al: Enolase 1 stimulates
glycolysis to promote chemore-sistance in gastric cancer.
Oncotarget. 8:47691–47708. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lu C, Shan Z, Li C and Yang L: MiR-129
regulates cisplatin-resistance in human gastric cancer cells by
targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar
|
|
88
|
Li B, Wang W, Li Z, Chen Z, Zhi X, Xu J,
Li Q, Wang L, Huang X, Wang L, et al: MicroRNA-148a-3p enhances
cisplatin cytotoxicity in gastric cancer through mitochondrial
fission induction and cyto-protective autophagy suppression. Cancer
Lett. 410:212–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ge X, Cui H, Zhou Y, Yin D, Feng Y, Xin Q,
Xu X, Liu W, Liu S and Zhang Q: miR-320a modulates cell growth and
chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med
Rep. 16:9664–9670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhao J, Nie Y, Wang H and Lin Y: MiR-181a
suppresses autophagy and sensitizes gastric cancer cells to
cisplatin. Gene. 576:828–833. 2016. View Article : Google Scholar
|
|
91
|
You HY, Xie XM, Zhang WJ, Zhu HL and Jiang
FZ: Berberine modulates cisplatin sensitivity of human gastric
cancer cells by upregulation of miR-203. In Vitro Cell Dev Biol
Anim. 52:857–863. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li X, Liang J, Liu YX, Wang Y, Yang XH,
Luan BH, Zhang GL, Du J and Wu XH: miR-149 reverses cisplatin
resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Pharmazie. 71:640–643. 2016.PubMed/NCBI
|
|
93
|
Zhuang M, Shi Q, Zhang X, Ding Y, Shan L,
Shan X, Qian J, Zhou X, Huang Z, Zhu W, et al: Involvement of
miR-143 in cisplatin resistance of gastric cancer cells via
targeting IGF1R and BCL2. Tumour Biol. 36:2737–2745. 2015.
View Article : Google Scholar
|
|
94
|
Wen L, Cheng F, Zhou Y and Yin C: MiR-26a
enhances the sensitivity of gastric cancer cells to cisplatin by
targeting NRAS and E2F2. Saudi J Gastroenterol. 21:313–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer. Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar
|
|
96
|
Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu
W, Shu Y and Liu P: MiR-503 regulates cisplatin resistance of human
gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J
(Engl). 127:2357–2362. 2014.
|
|
97
|
He J, Qi H, Chen F and Cao C: MicroRNA-25
contributes to cisplatin resistance in gastric cancer cells by
inhibiting forkhead box O3a. Oncol Lett. 14:6097–6102.
2017.PubMed/NCBI
|
|
98
|
Wang X, Zhang H, Bai M, Ning T, Ge S, Deng
T, Liu R, Zhang L, Ying G and Ba Y: Exosomes serve as nanoparticles
to deliver anti-miR-214 to reverse chemoresistance to cisplatin in
gastric cancer. Mol Ther. 26:774–783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Jia X, Li N, Peng C, Deng Y, Wang J, Deng
M, Lu M, Yin J, Zheng G, Liu H, et al: miR-493 mediated DKK1
down-regulation confers proliferation, invasion and
chemo-resistance in gastric cancer cells. Oncotarget. 7:7044–7054.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ge X, Liu X, Lin F, Li P, Liu K, Geng R,
Dai C, Lin Y, Tang W, Wu Z, et al: MicroRNA-421 regulated by HIF-1α
promotes metastasis, inhibits apoptosis, and induces cisplatin
resistance by targeting E-cadherin and caspase-3 in gastric cancer.
Oncotarget. 7:24466–24482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Chen DD, Feng LC, Ye R, He YQ and Wang YD:
miR-29b reduces cisplatin resistance of gastric cancer cell by
targeting PI3K/Akt pathway. Zhongguo Yi Xue Ke Xue Yuan Xue Bao.
37:514–519. 2015.In Chinese. PubMed/NCBI
|
|
102
|
Zhou X, Su J, Zhu L and Zhang G:
Helicobacter pylori modulates cisplatin sensitivity in gastric
cancer by down-regulating miR-141 expression. Helicobacter.
19:174–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang L, Guo X, Zhang D, Fan Y, Qin L,
Dong S and Zhang L: Upregulated miR-132 in Lgr5+ gastric
cancer stem cell-like cells contributes to cisplatin-resistance via
SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog. 56:2022–2034.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang J, Xue X, Hong H, Qin M, Zhou J, Sun
Q, Liang H and Gao L: Upregulation of microRNA-524-5p enhances the
cisplatin sensitivity of gastric cancer cells by modulating
proliferation and metastasis via targeting SOX9. Oncotarget.
8:574–582. 2017.
|
|
105
|
Zhang Z, Kong Y, Yang W, Ma F, Zhang Y, Ji
S, Ma EM, Liu H, Chen Y and Hua Y: Upregulation of microRNA-34a
enhances the DDP sensitivity of gastric cancer cells by modulating
proliferation and apoptosis via targeting MET. Oncol Rep.
36:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Jiang T, Dong P, Li L, Ma X, Xu P, Zhu H,
Wang Y, Yang B, Liu K, Liu J, et al: MicroRNA-200c regulates
cisplatin resistance by targeting ZEB2 in human gastric cancer
cells. Oncol Rep. 38:151–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chang L, Guo F, Wang Y, Lv Y, Huo B, Wang
L and Liu W: MicroRNA-200c regulates the sensitivity of
chemotherapy of gastric cancer SGC7901/DDP cells by directly
targeting RhoE. Pathol Oncol Res. 20:93–98. 2014. View Article : Google Scholar
|
|
108
|
Chen Y, Zuo J, Liu Y, Gao H and Liu W:
Inhibitory effects of miRNA-200c on chemotherapy-resistance and
cell proliferation of gastric cancer SGC7901/DDP cells. Chin J
Cancer. 29:1006–1011. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cheng C, Qin Y, Zhi Q, Wang J and Qin C:
Knockdown of long non-coding RNA HOTAIR inhibits cisplatin
resistance of gastric cancer cells through inhibiting the PI3K/Akt
and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int
J Biol Macromol. 107:2620–2629. 2018. View Article : Google Scholar
|
|
110
|
Yan J, Dang Y, Liu S, Zhang Y and Zhang G:
LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by
targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol.
37:16345–16355. 2016. View Article : Google Scholar
|
|
111
|
Zhou DD, Liu XF, Lu CW, Pant OP and Liu
XD: Long non-coding RNA PVT1: Emerging biomarker in digestive
system cancer. Cell Prolif. 50:502017. View Article : Google Scholar
|
|
112
|
Zhang XW, Bu P, Liu L, Zhang XZ and Li J:
Overexpression of long non-coding RNA PVT1 in gastric cancer cells
promotes the development of multidrug resistance. Biochem Biophys
Res Commun. 462:227–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang X, Bo P, Liu L, Zhang X and Li J:
Overexpression of long non-coding RNA GHET1 promotes the
development of multidrug resistance in gastric cancer cells. Biomed
Pharmacother. 92:580–585. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wang L, Chunyan Q, Zhou Y, He Q, Ma Y, Ga
Y and Wang X: BCAR4 increase cisplatin resistance and predicted
poor survival in gastric cancer patients. Eur Rev Med Pharmacol
Sci. 21:4064–4070. 2017.PubMed/NCBI
|
|
115
|
Hang Q, Sun R, Jiang C and Li Y: Notch 1
promotes cisplatin-resistant gastric cancer formation by
upregulating lncRNA AK022798 expression. Anticancer Drugs.
26:632–640. 2015.PubMed/NCBI
|
|
116
|
Li Y, Lv S, Ning H, Li K, Zhou X, Xv H and
Wen H: Down-regulation of CASC2 contributes to cisplatin resistance
in gastric cancer by sponging miR-19a. Biomed Pharmacother.
108:1775–1782. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li LQ, Pan D, Chen Q, Zhang SW, Xie DY,
Zheng XL and Chen H: Sensitization of gastric cancer cells to 5-FU
by microRNA-204 through targeting the TGFBR2-mediated epithelial to
mesenchymal transition. Cell Physiol Biochem. 47:1533–1545. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhang JX, Xu Y, Gao Y, Chen C, Zheng ZS,
Yun M, Weng HW, Xie D and Ye S: Decreased expression of miR-939
contributes to chemoresistance and metastasis of gastric cancer via
dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer.
16:182017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Korourian A, Roudi R, Shariftabrizi A and
Madjd Z: MicroRNA-31 inhibits RhoA-mediated tumor invasion and
chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp
Biol Med (Maywood). 242:1842–1847. 2017. View Article : Google Scholar
|
|
120
|
Choi H and Lee SK: TAX1BP1 downregulation
by EBV-miR-BART15-3p enhances chemosensitivity of gastric cancer
cells to 5-FU. Arch Virol. 162:369–377. 2017. View Article : Google Scholar
|
|
121
|
Xiong HL, Zhou SW, Sun AH, He Y, Li J and
Yuan X: MicroRNA 197 reverses the drug resistance of fluorouracil
induced SGC7901 cells by targeting mitogen activated protein kinase
1. Mol Med Rep. 12:5019–5025. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Jian B, Li Z, Xiao D, He G, Bai L and Yang
Q: Downregulation of microRNA-193-3p inhibits tumor proliferation
migration and chemoresistance in human gastric cancer by regulating
PTEN gene. Tumour Biol. 37:8941–8949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Han Y, Ye J, Wu D, Wu P, Chen Z, Chen J,
Gao S and Huang J: LEIGC long non-coding RNA acts as a tumor
suppressor in gastric carcinoma by inhibiting the
epithelial-to-mesenchymal transition. BMC Cancer. 14:9322014.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X,
Cai Y, Hu X and Liu Y: miR-103/107 modulates multidrug resistance
in human gastric carcinoma by downregulating Cav-1. Tumour Biol.
36:2277–2285. 2015. View Article : Google Scholar
|
|
125
|
Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y,
Liu L, Wang F, Li J, Yue Y, et al: Downregulation of histone
deacetylase 1 by microRNA-520h contributes to the chemotherapeutic
effect of doxorubicin. FEBS Lett. 588:184–191. 2014. View Article : Google Scholar
|
|
126
|
Chen J, Zhou C, Li J, Xiang X, Zhang L,
Deng J and Xiong J: miR-21-5p confers doxorubicin resistance in
gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med.
41:1855–1866. 2018.PubMed/NCBI
|
|
127
|
Zou J and Xu Y: MicroRNA-140 inhibits cell
proliferation in gastric cancer cell line HGC-27 by suppressing
SOX4. Med Sci Monit. 22:2243–2252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Pan Y, Ren F, Zhang W, Liu G, Yang D, Hu
J, Feng K and Feng Y: Regulation of BGC-823 cell sensitivity to
adriamycin via miRNA-135a-5p. Oncol Rep. 32:2549–2556. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang F, Li T, Zhang B, Li H, Wu Q, Yang L,
Nie Y, Wu K, Shi Y and Fan D: MicroRNA-19a/b regulates multidrug
resistance in human gastric cancer cells by targeting PTEN. Biochem
Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhou Z, Lin Z, He Y, Pang X, Wang Y,
Ponnusamy M, Ao X, Shan P, Tariq MA, Li P, et al: The long
noncoding RNA D63785 regulates chemotherapy sensitivity in human
gastric cancer by targeting miR-422a. Mol Ther Nucleic Acids.
12:405–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Zhang J, Zhao B, Chen X, Wang Z, Xu H and
Huang B: Silence of long noncoding RNA NEAT1 inhibits malignant
biological behaviors and chemotherapy resistance in gastric cancer.
Pathol Oncol Res. 24:109–113. 2018. View Article : Google Scholar
|
|
132
|
Cao W, Wei W, Zhan Z, Xie D, Xie Y and
Xiao Q: Regulation of drug resistance and metastasis of gastric
cancer cells via the microRNA647-ANK2 axis. Int J Mol Med.
41:1958–1966. 2018.PubMed/NCBI
|
|
133
|
Cao W, Wei W, Zhan Z, Xie Y and Xiao Q:
MiR-1284 modulates multidrug resistance of gastric cancer cells by
targeting EIF4A1. Oncol Rep. 35:2583–2591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar
|
|
135
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar
|
|
138
|
Yan LH, Chen ZN, Li-Li, Chen J, Wei WE, Mo
XW, Qin YZ, Lin Y and Chen JS: miR-135a promotes gastric cancer
progression and resistance to oxaliplatin. Oncotarget.
7:70699–70714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wu X, Zheng Y, Han B and Dong X: Long
noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin
resistance of gastric cancer via sponging miR-361. Biomed
Pharmacother. 99:832–838. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Yared JA and Tkaczuk KH: Update on taxane
development: New analogs and new formulations. Drug Des Devel Ther.
6:371–384. 2012.PubMed/NCBI
|
|
141
|
Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P
and Liu P: Regulation of microtubule-associated protein tau (MAPT)
by miR-34c-5p determines the chemosensitivity of gastric cancer to
paclitaxel. Cancer Chemother Pharmacol. 71:1159–1171. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Tian L, Zhao Z, Xie L and Zhu J:
MiR-361-5p suppresses chemoresistance of gastric cancer cells by
targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget.
9:4886–4896. 2017.
|
|
143
|
Kang YK, Ryoo BY, Yoon S, Shen L, Lee J,
Wei C, Zhou Y and Ryu MH: A Phase I study of cabazitaxel in
patients with advanced gastric cancer who have failed prior
chemotherapy (GASTANA). Cancer Chemother Pharmacol. 75:309–318.
2015. View Article : Google Scholar
|
|
144
|
Ju C, Wen Y, Zhang L, Wang Q, Xue L, Shen
J and Zhang C: Neoadjuvant chemotherapy based on abraxane/human
neutrophils cytopharmaceuticals with radiotherapy for gastric
cancer. Small. 15:e18041912018. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Simón-Gracia L, Hunt H, Scodeller PD,
Gaitzsch J, Braun GB, Willmore AM, Ruoslahti E, Battaglia G and
Teesalu T: Paclitaxel-loaded polymersomes for enhanced
intraperitoneal chemotherapy. Mol Cancer Ther. 15:670–679. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Harada K, Mizrak Kaya D, Shimodaira Y and
Ajani JA: Global chemotherapy development for gastric cancer.
Gastric Cancer. 20(Suppl 1): 92–101. 2017. View Article : Google Scholar
|
|
147
|
Venturutti L, Cordo Russo RI, Rivas MA,
Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M,
Proietti CJ, Yankilevich P, et al: MiR-16 mediates trastuzumab and
lapatinib response in ErbB-2-positive breast and gastric cancer via
its novel targets CCNJ and FUBP1. Oncogene. 35:6189–6202. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Abril-Rodriguez G and Ribas A: SnapShot:
Immune checkpoint inhibitors. Cancer Cell. 31:848–848.e841. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Kamath SD, Kalyan A and Benson AB III:
Pembrolizumab for the treatment of gastric cancer. Expert Rev
Anticancer Ther. 18:1177–1187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Smolle MA, Calin HN, Pichler M and Calin
GA: Noncoding RNAs and immune checkpoints-clinical implications as
cancer therapeutics. FEBS J. 284:1952–1966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu
S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, et al: MiR-138
exerts anti-glioma efficacy by targeting immune checkpoints. Neuro
Oncol. 18:639–648. 2016. View Article : Google Scholar :
|
|
156
|
Fujita Y, Yagishita S, Hagiwara K,
Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H,
Tamura T, et al: The clinical relevance of the
miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant
non-small-cell lung cancer. Mol Ther. 23:717–727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Bullock MD, Silva AM, Kanlikilicer-Unaldi
P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G and Calin GA:
Exosomal non-coding RNAs: Diagnostic, prognostic and therapeutic
applications in cancer. Noncoding RNA. 1:53–68. 2015.PubMed/NCBI
|
|
158
|
Bullrich F, Fujii H, Calin G, Mabuchi H,
Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, et
al: Characterization of the 13q14 tumor suppressor locus in CLL:
Identification of ALT1, an alternative splice variant of the LEU2
gene. Cancer Res. 61:6640–6648. 2001.PubMed/NCBI
|
|
159
|
Bader AG, Brown D and Winkler M: The
promise of microRNA replacement therapy. Cancer Res. 70:7027–7030.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Gandellini P, Profumo V, Folini M and
Zaffaroni N: MicroRNAs as new therapeutic targets and tools in
cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
van der Ree MH, van der Meer AJ, van
Nuenen AC, de Bruijne J, Ottosen S, Janssen HL, Kootstra NA and
Reesink HW: Miravirsen dosing in chronic hepatitis C patients
results in decreased microRNA-122 levels without affecting other
microRNAs in plasma. Aliment Pharmacol Ther. 43:102–113. 2016.
View Article : Google Scholar
|
|
162
|
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem
S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A,
Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N
Engl J Med. 368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J,
Liu L, Ling R, Yi J, Wang L, et al: Three dysregulated microRNAs in
serum as novel biomarkers for gastric cancer screening. Med Oncol.
31:2982014. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kim CH, Kim HK, Rettig RL, Kim J, Lee ET,
Aprelikova O, Choi IJ, Munroe DJ and Green JE: miRNA signature
associated with outcome of gastric cancer patients following
chemotherapy. BMC Med Genomics. 4:792011. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi
T and Yousefi M: MicroRNA-induced drug resistance in gastric
cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Baumann V and Winkler J: miRNA-based
therapies: Strategies and delivery platforms for oligonucleotide
and non-oligonu-cleotide agents. Future Med Chem. 6:1967–1984.
2014. View Article : Google Scholar
|
|
168
|
Boudreau RL, Martins I and Davidson BL:
Artificial microRNAs as siRNA shuttles: Improved safety as compared
to shRNAs in vitro and in vivo. Mol Ther. 17:169–175. 2009.
View Article : Google Scholar
|
|
169
|
Safaei R, Larson BJ, Cheng TC, Gibson MA,
Otani S, Naerdemann W and Howell SB: Abnormal lysosomal trafficking
and enhanced exosomal export of cisplatin in drug-resistant human
ovarian carcinoma cells. Mol Cancer Ther. 4:1595–1604. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ciravolo V, Huber V, Ghedini GC,
Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della
Mina P, Menard S, et al: Potential role of HER2-overexpressing
exosomes in countering trastuzumab-based therapy. J Cell Physiol.
227:658–667. 2012. View Article : Google Scholar
|
|
171
|
Zhang HD, Jiang LH, Hou JC, Zhong SL, Zhu
LP, Wang DD, Zhou SY, Yang SJ, Wang JY, Zhang Q, et al: Exosome: A
novel mediator in drug resistance of cancer cells. Epigenomics.
10:1499–1509. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Shuwen H, Qing Z, Yan Z and Xi Y:
Competitive endogenous RNA in colorectal cancer: A systematic
review. Gene. 645:157–162. 2018. View Article : Google Scholar
|
|
173
|
Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y,
Chen W, Liu F, Sun W, Li XF, et al: Exosome-transmitted lncARSR
promotes sunitinib resistance in renal cancer by acting as a
competing endogenous RNA. Cancer Cell. 29:653–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Wang D, Yang S, Wang H, Wang J, Zhang Q,
Zhou S, He Y, Zhang H, Deng F, Xu H, et al: The progress of
circular RNAs in various tumors. Am J Transl Res. 10:1571–1582.
2018.PubMed/NCBI
|
|
175
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
Overexpressed circPVT1, a potential new circular RNA biomarker,
contributes to doxorubicin and cisplatin resistance of osteosarcoma
cells by regulating ABCB1. Int J Biol Sci. 14:321–330. 2018.
View Article : Google Scholar : PubMed/NCBI
|
